US5922253A
(en)
*
|
1995-05-18 |
1999-07-13 |
Alkermes Controlled Therapeutics, Inc. |
Production scale method of forming microparticles
|
US5989463A
(en)
*
|
1997-09-24 |
1999-11-23 |
Alkermes Controlled Therapeutics, Inc. |
Methods for fabricating polymer-based controlled release devices
|
US6723517B1
(en)
*
|
1998-06-02 |
2004-04-20 |
Minerva Biotechnologies Corporation |
Use of self-assembled monolayers to probe the structure of a target molecule
|
US6387410B1
(en)
|
1998-09-10 |
2002-05-14 |
Norton Healthcare Ltd |
Anti-inflammatory pharmaceutical formulations
|
US6514525B2
(en)
|
1998-09-10 |
2003-02-04 |
Norton Healthcare Ltd |
Anti-inflammatory pharmaceutical formulations
|
EP1074248A1
(de)
*
|
1999-07-08 |
2001-02-07 |
Arnold Hilgers |
Verabreichungssystem für biologisches Material
|
US6458387B1
(en)
*
|
1999-10-18 |
2002-10-01 |
Epic Therapeutics, Inc. |
Sustained release microspheres
|
DE60142614D1
(de)
|
2000-01-27 |
2010-09-02 |
Medimmune Inc |
Inität
|
US7229619B1
(en)
|
2000-11-28 |
2007-06-12 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
AU2002219944B2
(en)
|
2000-11-28 |
2008-02-21 |
Medimmune, Llc |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
DK1259547T3
(da)
|
2000-03-01 |
2012-10-15 |
Medimmune Inc |
Højpotente, rekombinante antistoffer og fremgangsmåde til fremstilling heraf
|
US7074803B2
(en)
*
|
2001-03-02 |
2006-07-11 |
Durect Corporation |
Opioid formulations
|
DE60140625D1
(de)
*
|
2000-08-15 |
2010-01-07 |
Univ Illinois |
Verfahren zur herstellung von mikropartikeln
|
US6824822B2
(en)
*
|
2001-08-31 |
2004-11-30 |
Alkermes Controlled Therapeutics Inc. Ii |
Residual solvent extraction method and microparticles produced thereby
|
US7666445B2
(en)
|
2000-10-20 |
2010-02-23 |
The Trustees Of The University Of Pennsylvania |
Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
|
DE60138641D1
(de)
|
2000-10-27 |
2009-06-18 |
Baxter Healthcare Sa |
Herstellung von mikrokügelchen
|
US6818216B2
(en)
*
|
2000-11-28 |
2004-11-16 |
Medimmune, Inc. |
Anti-RSV antibodies
|
US7179900B2
(en)
|
2000-11-28 |
2007-02-20 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
US6855493B2
(en)
|
2000-11-28 |
2005-02-15 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
EP2341060B1
(de)
|
2000-12-12 |
2019-02-20 |
MedImmune, LLC |
Moleküle mit längeren Halbwertszeiten, Zusammensetzungen und deren Verwendung
|
WO2002051438A2
(en)
|
2000-12-22 |
2002-07-04 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Use of repulsive guidance molecule (rgm) and its modulators
|
WO2002098370A2
(en)
*
|
2001-03-02 |
2002-12-12 |
Medimmune, Inc. |
Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
|
US6730772B2
(en)
|
2001-06-22 |
2004-05-04 |
Venkatram P. Shastri |
Degradable polymers from derivatized ring-opened epoxides
|
ES2307779T3
(es)
*
|
2001-08-16 |
2008-12-01 |
Baxter International Inc. |
Formulaciones de microparticulas a base de propelentes.
|
US6818613B2
(en)
|
2001-11-07 |
2004-11-16 |
Ortho-Mcneil Pharmaceutical, Inc. |
Aqueous sustained-release formulations of proteins
|
US8133501B2
(en)
|
2002-02-08 |
2012-03-13 |
Boston Scientific Scimed, Inc. |
Implantable or insertable medical devices for controlled drug delivery
|
US8685427B2
(en)
|
2002-07-31 |
2014-04-01 |
Boston Scientific Scimed, Inc. |
Controlled drug delivery
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
US7425618B2
(en)
*
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
EP1534327A4
(de)
*
|
2002-07-25 |
2006-08-23 |
Medimmune Inc |
Verfahren zur behandlung und prävention von rsv, hmpv, und piv mit anti-rsv-, anti-hmpv- und anti-piv-antikörpern
|
US8920826B2
(en)
|
2002-07-31 |
2014-12-30 |
Boston Scientific Scimed, Inc. |
Medical imaging reference devices
|
EP2371389A3
(de)
|
2002-08-14 |
2012-04-18 |
MacroGenics, Inc. |
FC-Gamma-RIIB-spezifische Antikörper und Verwendungsverfahren davon
|
DE60336406D1
(de)
|
2002-10-16 |
2011-04-28 |
Purdue Pharma Lp |
Antikörper, die an zellassoziiertes ca 125/0722p binden, und verfahren zu deren anwendung
|
US6800663B2
(en)
*
|
2002-10-18 |
2004-10-05 |
Alkermes Controlled Therapeutics Inc. Ii, |
Crosslinked hydrogel copolymers
|
KR100709015B1
(ko)
*
|
2002-11-13 |
2007-04-18 |
(주)아모레퍼시픽 |
지속적 약물방출이 가능한 고분자 미립구 및 그 제조방법
|
WO2004062599A2
(en)
|
2003-01-06 |
2004-07-29 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
EP2368578A1
(de)
|
2003-01-09 |
2011-09-28 |
Macrogenics, Inc. |
Identifizierung und Herstellung von Antikörpern mit abweichenden FC-Regionen und Anwendungsverfahren dafür
|
EP2272533A1
(de)
|
2003-01-13 |
2011-01-12 |
MacroGenics, Inc. |
Lösliche FcyR-Fusionsproteine und Verfahren zu deren Verwendung
|
US7658998B2
(en)
*
|
2003-01-22 |
2010-02-09 |
Alkermes Controlled Therapeutics, Inc. |
Method of preparing sustained release microparticles
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
DK2865385T3
(en)
|
2003-02-04 |
2016-12-19 |
Cornell Res Foundation Inc |
Applications of the aromatic-cationic peptide
|
US7736391B2
(en)
|
2003-02-06 |
2010-06-15 |
Tonaba Healthscience Ii, Llc |
Cosmetic and reconstructive prostheses with a microencapsulated biologically compatible rupture indicator for sustained release and methods of detecting compromise of a prosthesis
|
AU2004224530A1
(en)
*
|
2003-03-26 |
2004-10-07 |
Ltt Bio-Pharma Co., Ltd. |
Intravenous nanoparticles for targenting drug delivery and sustained drug release
|
US7354584B2
(en)
|
2003-04-11 |
2008-04-08 |
Medimmune, Inc. |
Recombinant IL-9 antibodies
|
BRPI0409911A
(pt)
|
2003-05-01 |
2006-04-25 |
Cornell Res Foundation Inc |
método para liberar uma molécula em uma célula, e, complexo carreador
|
US7326571B2
(en)
*
|
2003-07-17 |
2008-02-05 |
Boston Scientific Scimed, Inc. |
Decellularized bone marrow extracellular matrix
|
US20050142205A1
(en)
*
|
2003-07-18 |
2005-06-30 |
Julia Rashba-Step |
Methods for encapsulating small spherical particles prepared by controlled phase separation
|
SG135204A1
(en)
*
|
2003-07-18 |
2007-09-28 |
Baxter Int |
Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation
|
US20070092452A1
(en)
*
|
2003-07-18 |
2007-04-26 |
Julia Rashba-Step |
Methods for fabrication, uses, compositions of inhalable spherical particles
|
US20050048127A1
(en)
*
|
2003-07-22 |
2005-03-03 |
Larry Brown |
Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
|
EP2272566A3
(de)
|
2003-08-18 |
2013-01-02 |
MedImmune, LLC |
Humanisierung von antikörpern
|
WO2005037232A2
(en)
|
2003-10-17 |
2005-04-28 |
Joslin Diabetes Center, Inc. |
Methods and compositions for modulating adipocyte function
|
US7309500B2
(en)
*
|
2003-12-04 |
2007-12-18 |
The Board Of Trustees Of The University Of Illinois |
Microparticles
|
US20060053516A1
(en)
*
|
2003-12-05 |
2006-03-09 |
The University Of Hong Kong |
Genetically modified plants comprising SARS-CoV viral nucleotide sequences and methods of use thereof for immunization against SARS
|
US7371381B2
(en)
|
2003-12-12 |
2008-05-13 |
Amgen Inc. |
Anti-galanin antibodies and uses thereof
|
US8329203B2
(en)
|
2004-01-12 |
2012-12-11 |
The Trustees Of The University Of Pennsylvania |
Drug-containing implants and methods of use thereof
|
US8221778B2
(en)
|
2005-01-12 |
2012-07-17 |
The Trustees Of The University Of Pennsylvania |
Drug-containing implants and methods of use thereof
|
WO2005072702A2
(en)
*
|
2004-01-20 |
2005-08-11 |
Alkermes Controlled Therapeutics, Inc. |
Method for milling frozen microparticles
|
CA2554166C
(en)
|
2004-01-23 |
2014-07-29 |
Cornell Research Foundation, Inc. |
Methods for reducing oxidative damage
|
WO2005110425A1
(en)
|
2004-04-15 |
2005-11-24 |
Alkermes, Inc. |
Polymer-based sustained release device
|
CN103393601A
(zh)
|
2004-05-12 |
2013-11-20 |
巴克斯特国际公司 |
含有蛋白并在高浓度蛋白下显示可注射性的微球体
|
AU2005244851B2
(en)
|
2004-05-12 |
2010-08-26 |
Baxter Healthcare S.A. |
Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1
|
US8728525B2
(en)
|
2004-05-12 |
2014-05-20 |
Baxter International Inc. |
Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
|
JP2007537284A
(ja)
|
2004-05-12 |
2007-12-20 |
バクスター インターナショナル インコーポレイテッド |
核酸マイクロスフェア、その生成および送達
|
WO2006012394A1
(en)
|
2004-07-21 |
2006-02-02 |
Tulane University Health Sciences Center |
Treatment of renal dysfunction and multiple myeloma using pacap compounds
|
CA2580921C
(en)
|
2004-09-21 |
2016-04-12 |
Medimmune, Inc. |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
AU2005299355A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune, Llc |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
EP1812068A4
(de)
*
|
2004-10-29 |
2010-06-09 |
Medimmune Inc |
Verfahren zur prävention und behandlung von rsv-infektionen und verwandten leiden
|
US7748343B2
(en)
|
2004-11-22 |
2010-07-06 |
The Board Of Trustees Of The University Of Illinois |
Electrohydrodynamic spraying system
|
US20060165667A1
(en)
*
|
2004-12-03 |
2006-07-27 |
Case Western Reserve University |
Novel methods, compositions and devices for inducing neovascularization
|
WO2006078841A1
(en)
*
|
2005-01-21 |
2006-07-27 |
President And Fellows Of Harvard College |
Systems and methods for forming fluidic droplets encapsulated in particles such as colloidal particles
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
CA2602035C
(en)
|
2005-03-18 |
2015-06-16 |
Medimmune, Inc. |
Framework-shuffling of antibodies
|
US9296816B2
(en)
|
2005-04-15 |
2016-03-29 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
WO2006116565A2
(en)
*
|
2005-04-25 |
2006-11-02 |
Amgen Inc. |
Biodegradable peptide sustained release compositions containing porogens
|
US8017152B2
(en)
|
2005-05-27 |
2011-09-13 |
Stratosphere Pharma Ab |
Cores and microcapsules suitable for parenteral administration as well as process for their manufacture
|
US20070110757A1
(en)
|
2005-06-23 |
2007-05-17 |
Ziping Wei |
Antibody formulations having optimized aggregation and fragmentation profiles
|
US7700739B2
(en)
|
2005-06-30 |
2010-04-20 |
Abbott Laboratories |
IL-12/p40 binding proteins
|
DK1919503T3
(en)
|
2005-08-10 |
2014-12-15 |
Macrogenics Inc |
Identification and preparation of antibodies with variant fc regions and methods of use thereof
|
EP2500359A3
(de)
|
2005-08-19 |
2012-10-17 |
Abbott Laboratories |
Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
|
US20090215992A1
(en)
*
|
2005-08-19 |
2009-08-27 |
Chengbin Wu |
Dual variable domain immunoglobulin and uses thereof
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
CN101370525B
(zh)
|
2005-08-19 |
2013-09-18 |
Abbvie公司 |
双重可变结构域免疫球蛋白及其用途
|
CN101296704B
(zh)
|
2005-09-16 |
2012-09-05 |
科内尔研究基金会 |
用于减少cd36表达的方法
|
ES2542501T3
(es)
|
2005-09-30 |
2015-08-06 |
Abbvie Deutschland Gmbh & Co Kg |
Dominios de unión de proteínas de la familia de proteínas de moléculas de orientación repulsiva (RGM) y fragmentos funcionales de las mismas, así como su uso
|
EP2289909B1
(de)
|
2005-11-30 |
2014-10-29 |
AbbVie Inc. |
Screeningsverfahren, Verfahren zur Reinigung von nicht-diffundierenden Beta-Oligomeren, selektive Antikörper gegen genannten nichtdiffundierende Beta-Oligomere und Verfahren zur Herstellung von genannten Antikörpern
|
CN102898519B
(zh)
|
2005-11-30 |
2015-10-28 |
Abbvie公司 |
抗淀粉样β蛋白的单克隆抗体及其用途
|
WO2007074604A1
(ja)
*
|
2005-12-26 |
2007-07-05 |
Ltt Bio-Pharma Co., Ltd. |
水溶性非ペプチド性低分子薬物含有ナノ粒子
|
US20080058316A1
(en)
|
2006-02-27 |
2008-03-06 |
The Johns Hopkins University |
Cancer treatment with gama-secretase inhibitors
|
US8747870B2
(en)
|
2006-04-20 |
2014-06-10 |
University Of Utah Research Foundation |
Polymeric compositions and methods of making and using thereof
|
EP2012803A4
(de)
*
|
2006-04-20 |
2012-08-01 |
Univ Utah Res Found |
Polymerzusammensetzungen sowie verfahren zu ihrer herstellung und verwendung
|
US20070281031A1
(en)
*
|
2006-06-01 |
2007-12-06 |
Guohan Yang |
Microparticles and methods for production thereof
|
SG177907A1
(en)
|
2006-06-14 |
2012-02-28 |
Macrogenics Inc |
Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
|
EP2505209A1
(de)
|
2006-06-26 |
2012-10-03 |
MacroGenics, Inc. |
Fcgamma-RIIB-spezifische Antikörper und Verfahren zu ihrer Anwendung
|
US20080075777A1
(en)
*
|
2006-07-31 |
2008-03-27 |
Kennedy Michael T |
Apparatus and methods for preparing solid particles
|
WO2008019346A2
(en)
|
2006-08-04 |
2008-02-14 |
Baxter International Inc. |
Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
|
EP3421031A1
(de)
|
2006-08-09 |
2019-01-02 |
Intarcia Therapeutics, Inc |
Osmotisches verabreichungssystem mit kolbenanordnung
|
BRPI0716088B8
(pt)
|
2006-08-28 |
2021-05-25 |
Kyowa Hakko Kirin Co Ltd |
anticorpo isolado, composição, molécula de ácido nucléico isolada, vetor, método para produzir um anticorpo, hibridoma, e, kit
|
CA3007075C
(en)
|
2006-09-07 |
2019-10-15 |
Arthur E. Frankel |
Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
|
HUE052220T2
(hu)
|
2006-09-08 |
2021-04-28 |
Abbvie Bahamas Ltd |
Interleukin-13 kötõfehérjék
|
EP2064335A4
(de)
|
2006-10-16 |
2011-03-30 |
Medimmune Llc |
Moleküle mit reduzierter halbwertzeit, zusammensetzungen und ihre verwendung
|
US20080121733A1
(en)
*
|
2006-11-29 |
2008-05-29 |
Donald Ackley |
Droplet generating device and method
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
EP2094246B1
(de)
|
2006-12-18 |
2020-04-01 |
Takeda Pharmaceutical Company Limited |
Zusammensetzung mit verzögerter freisetzung und herstellungsverfahren dafür
|
WO2008101116A1
(en)
*
|
2007-02-14 |
2008-08-21 |
Brigham And Women's Hospital, Inc. |
Crosslinked polymers and methods of making the same
|
US8895004B2
(en)
|
2007-02-27 |
2014-11-25 |
AbbVie Deutschland GmbH & Co. KG |
Method for the treatment of amyloidoses
|
CN101715340A
(zh)
|
2007-04-23 |
2010-05-26 |
精达制药公司 |
促胰岛素释放肽的混悬制剂及其应用
|
WO2008134807A1
(en)
*
|
2007-05-04 |
2008-11-13 |
The University Of Sydney |
Method for manufacturing a porous polymer matrix
|
KR101513318B1
(ko)
*
|
2007-05-14 |
2015-04-17 |
가부시키가이샤 엘티티 바이오파마 |
서방성의 음하전기를 갖는 저분자 약물 함유 나노 입자
|
US20090232801A1
(en)
*
|
2007-05-30 |
2009-09-17 |
Abbot Laboratories |
Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
|
PE20090329A1
(es)
*
|
2007-05-30 |
2009-03-27 |
Abbott Lab |
Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
|
EP1997830A1
(de)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
|
CA2691434C
(en)
|
2007-06-21 |
2020-07-21 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
CA2694488A1
(en)
|
2007-07-31 |
2009-02-05 |
Medimmune, Llc |
Multispecific epitope binding proteins and uses thereof
|
EP2222281B1
(de)
|
2007-12-20 |
2018-12-05 |
Evonik Corporation |
Verfahren zur herstellung von mikropartikeln mit geringer restlösemittelmenge
|
BRPI0907046A2
(pt)
|
2008-01-18 |
2015-07-28 |
Medimmune Llc |
Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo
|
US8420088B2
(en)
|
2008-01-28 |
2013-04-16 |
Novartis Ag |
Methods and compositions using FGF23 fusion polypeptides
|
TW200936156A
(en)
|
2008-01-28 |
2009-09-01 |
Novartis Ag |
Methods and compositions using Klotho-FGF fusion polypeptides
|
CA2713150C
(en)
|
2008-02-07 |
2016-01-05 |
Cornell University |
Methods for preventing or treating insulin resistance
|
EP2240155B1
(de)
|
2008-02-13 |
2012-06-06 |
Intarcia Therapeutics, Inc |
Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
|
EP2262520B1
(de)
|
2008-02-26 |
2017-05-03 |
Cornell University |
Zusammensetzungen zur prävention und behandlung von nierenschädigung
|
CN102123745A
(zh)
*
|
2008-02-29 |
2011-07-13 |
科洛普拉斯特公司 |
用于受试者中活组织的增加和再生的组合物和方法
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
SG190572A1
(en)
|
2008-04-29 |
2013-06-28 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
US20110104133A1
(en)
|
2008-05-06 |
2011-05-05 |
Joslin Diabetes Center, Inc. |
Methods and compositions for inducing brown adipogenesis
|
JP5890174B2
(ja)
|
2008-05-09 |
2016-03-22 |
アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー |
終末糖化産物受容体(rage)に対する抗体及びその使用
|
US9109026B2
(en)
|
2008-06-03 |
2015-08-18 |
Abbvie, Inc. |
Dual variable domain immunoglobulins and uses thereof
|
RU2010153580A
(ru)
|
2008-06-03 |
2012-07-20 |
Эбботт Лэборетриз (Us) |
Иммуноглобулины с двумя вариабельными доменами и их применение
|
WO2009158724A2
(en)
*
|
2008-06-27 |
2009-12-30 |
Tepha, Inc. |
Improved injectable delivery of microparticles and compositions therefore
|
BRPI0915825A2
(pt)
|
2008-07-08 |
2015-11-03 |
Abbott Lab |
proteínas de ligação à prostaglandina e2 usos das mesmas
|
MX2010014574A
(es)
|
2008-07-08 |
2011-04-27 |
Abbott Lab |
Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
|
US8367427B2
(en)
|
2008-08-20 |
2013-02-05 |
Baxter International Inc. |
Methods of processing compositions containing microparticles
|
US8323685B2
(en)
|
2008-08-20 |
2012-12-04 |
Baxter International Inc. |
Methods of processing compositions containing microparticles
|
US8323615B2
(en)
|
2008-08-20 |
2012-12-04 |
Baxter International Inc. |
Methods of processing multi-phasic dispersions
|
CA2999537C
(en)
|
2008-10-10 |
2021-10-19 |
Dana-Farber Cancer Institute |
Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides
|
EP2344578A2
(de)
*
|
2008-10-30 |
2011-07-20 |
David Liu |
Mikrosphärische poröse biokompatible gerüste und verfahren und gerät zu ihrer herstellung
|
WO2010068684A2
(en)
|
2008-12-09 |
2010-06-17 |
Dana Farber Cancer Institute, Inc. |
Methods and compositions for specific modulation of mcl-1
|
CN106220734A
(zh)
|
2008-12-19 |
2016-12-14 |
宏观基因有限公司 |
共价双抗体及其用途
|
WO2010085607A1
(en)
*
|
2009-01-23 |
2010-07-29 |
Surmodics Pharmaceuticals, Inc. |
Continuous double emulsion process for making microparticles
|
US20110165063A1
(en)
*
|
2009-01-29 |
2011-07-07 |
Abbott Laboratories |
Il-1 binding proteins
|
BRPI1007371A2
(pt)
*
|
2009-01-29 |
2018-03-27 |
Abbott Lab |
proteínas de ligação a il-1
|
WO2010087927A2
(en)
|
2009-02-02 |
2010-08-05 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
US8030026B2
(en)
|
2009-02-24 |
2011-10-04 |
Abbott Laboratories |
Antibodies to troponin I and methods of use thereof
|
TWI541021B
(zh)
|
2009-03-05 |
2016-07-11 |
艾伯維有限公司 |
Il-17結合蛋白
|
US8283162B2
(en)
|
2009-03-10 |
2012-10-09 |
Abbott Laboratories |
Antibodies relating to PIVKAII and uses thereof
|
WO2010120431A2
(en)
|
2009-03-20 |
2010-10-21 |
The General Hospital Corporation D/B/A Massachusetts General Hospital |
Methods for the prevention and treatment of burn injuries and secondary complications
|
WO2010141329A1
(en)
|
2009-06-01 |
2010-12-09 |
Medimmune, Llc |
Molecules with extended half-lives and uses thereof
|
JP5918129B2
(ja)
|
2009-06-22 |
2016-05-18 |
メディミューン,エルエルシー |
部位特異的共役のための操作されたFc領域
|
KR101778317B1
(ko)
|
2009-08-13 |
2017-09-13 |
얀센 백신스 앤드 프리벤션 비.브이. |
사람 호흡기 세포융합 바이러스(rsv)에 대한 항체 및 이용 방법
|
PL2470191T3
(pl)
|
2009-08-24 |
2014-09-30 |
Stealth Peptides Int Inc |
Sposoby i kompozycje do profilaktyki lub leczenia stanów okulistycznych
|
CN105131112A
(zh)
|
2009-08-29 |
2015-12-09 |
Abbvie公司 |
治疗用dll4结合蛋白
|
WO2011028811A2
(en)
*
|
2009-09-01 |
2011-03-10 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
WO2011035205A2
(en)
|
2009-09-18 |
2011-03-24 |
Calmune Corporation |
Antibodies against candida, collections thereof and methods of use
|
SI2462246T1
(en)
|
2009-09-28 |
2018-01-31 |
Intarcia Therapeutics, Inc. |
Fast-setting and / or cessation of substantially unchanged delivery of the product
|
JP2013506696A
(ja)
|
2009-10-05 |
2013-02-28 |
コーネル ユニヴァーシティー |
心不全の予防又は処置の方法
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
EP2486141B1
(de)
|
2009-10-07 |
2018-01-10 |
MacroGenics, Inc. |
Fc-regionshaltige polypeptide mit besserer effektorfunktion aufgrund von änderungen des ausmasses einer fukosylierung sowie verwendungsverfahren dafür
|
CN102666875A
(zh)
|
2009-10-15 |
2012-09-12 |
雅培制药有限公司 |
双重可变结构域免疫球蛋白及其用途
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
US8420083B2
(en)
*
|
2009-10-31 |
2013-04-16 |
Abbvie Inc. |
Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
|
CA2779496A1
(en)
|
2009-11-02 |
2011-05-05 |
The Administrators Of The Tulane Educational Fund |
Analogs of pitutary adenylate cyclase-activating polypeptide (pacap) and methods for their use
|
AU2010329955A1
(en)
|
2009-12-08 |
2012-05-24 |
Abbott Gmbh & Co. Kg |
Monoclonal antibodies against the RGM A protein for use in the treatment of retinal nerve fiber layer degeneration
|
EP3266462A1
(de)
|
2009-12-31 |
2018-01-10 |
Stealth Peptides International, Inc. |
Verfahren zur durchführung eines koronararterien-bypass-verfahrens
|
EP2519248A4
(de)
|
2009-12-31 |
2013-06-26 |
Stealth Peptides Int Inc |
Verfahren zur vorbeugung oder behandlung einer gefässverschlussverletzung
|
CA3008993A1
(en)
|
2010-01-25 |
2011-07-28 |
Cornell University |
Aromatic-cationic peptides and uses of same
|
US20130040901A1
(en)
|
2010-02-26 |
2013-02-14 |
University Of Florida Research Foundation Inc. |
Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
|
KR20180044441A
(ko)
|
2010-03-02 |
2018-05-02 |
애브비 인코포레이티드 |
치료학적 dll4 결합 단백질
|
EP3040080A1
(de)
|
2010-03-15 |
2016-07-06 |
Stealth Peptides International, Inc. |
Kombinationstherapien mit cyclosporin und aromatischen kationischen peptiden
|
WO2011130377A2
(en)
|
2010-04-15 |
2011-10-20 |
Abbott Laboratories |
Amyloid-beta binding proteins
|
EP3130599A1
(de)
|
2010-05-03 |
2017-02-15 |
Stealth Peptides International, Inc. |
Aromatische-kationische peptide und verwendungen davon
|
SG185416A1
(en)
|
2010-05-06 |
2012-12-28 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
|
CA2798390A1
(en)
|
2010-05-06 |
2011-11-10 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
|
LT2571532T
(lt)
|
2010-05-14 |
2017-08-10 |
Abbvie Inc. |
Il-1 surišantys baltymai
|
US20120009196A1
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
US9345738B2
(en)
|
2010-07-09 |
2016-05-24 |
Stealth Biotherapeutics Corp. |
Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
TWI627964B
(zh)
|
2010-07-09 |
2018-07-01 |
傑森疫苗防護公司 |
抗-人類呼吸道融合性病毒(rsv)抗體及其使用方法
|
US9120862B2
(en)
|
2010-07-26 |
2015-09-01 |
Abbott Laboratories |
Antibodies relating to PIVKA-II and uses thereof
|
EP2601216B1
(de)
|
2010-08-02 |
2018-01-03 |
MacroGenics, Inc. |
Kovalente diabodies und deren verwendung
|
PE20131412A1
(es)
|
2010-08-03 |
2014-01-19 |
Abbvie Inc |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
CA2808187A1
(en)
|
2010-08-14 |
2012-02-23 |
Abbvie Inc. |
Amyloid-beta binding proteins
|
PT3333188T
(pt)
|
2010-08-19 |
2022-03-28 |
Zoetis Belgium S A |
Anticorpos de anti-ngf e a sua utilização
|
CN103080134B
(zh)
|
2010-08-20 |
2015-11-25 |
诺华股份有限公司 |
表皮生长因子受体3(her3)的抗体
|
TW201211252A
(en)
|
2010-08-26 |
2012-03-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
WO2012050673A1
(en)
|
2010-10-14 |
2012-04-19 |
Wisconsin Alumni Research Foundation |
Methods for the treatment of x-linked hypophosphatemia and related disorders
|
EP2643353A1
(de)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Multispezifische moleküle
|
PE20141060A1
(es)
|
2010-12-21 |
2014-09-26 |
Abbvie Inc |
Inmunoglobulinas de dominio variable dual biespecificas de il-1 alfa y beta y su uso
|
US20120275996A1
(en)
|
2010-12-21 |
2012-11-01 |
Abbott Laboratories |
IL-1 Binding Proteins
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
CN107219358A
(zh)
|
2011-03-24 |
2017-09-29 |
康奈尔大学 |
芳香族阳离子肽及其用途
|
HUE037651T2
(hu)
|
2011-04-20 |
2018-09-28 |
Medimmune Llc |
B7-Hl-et és PD-l-et kötõ ellenanyagok és más molekulák
|
AU2012259162C1
(en)
|
2011-05-21 |
2020-05-21 |
Macrogenics, Inc. |
Deimmunized serum-binding domains and their use for extending serum half-life
|
AU2012283039A1
(en)
|
2011-07-13 |
2014-01-30 |
Abbvie Inc. |
Methods and compositions for treating asthma using anti-IL-13 antibodies
|
JP6120848B2
(ja)
|
2011-08-15 |
2017-04-26 |
メディミューン,エルエルシー |
抗b7−h4抗体およびその使用
|
WO2013027191A1
(en)
|
2011-08-25 |
2013-02-28 |
Novartis Ag |
Methods and compositions using fgf23 fusion polypeptides
|
BR112014006929A2
(pt)
|
2011-09-23 |
2017-04-04 |
Technophage Investigação E Desenvolvimento Em Biotecnologia Sa |
agentes anti-fator de necrose tumoral-alfa e seus usos
|
CN103987397A
(zh)
|
2011-09-29 |
2014-08-13 |
梅约医学教育与研究基金会 |
芳族阳离子肽和使用它们的方法
|
CA2852454A1
(en)
|
2011-10-17 |
2013-04-25 |
Cornell University |
Aromatic-cationic peptides and uses of same
|
TW201323440A
(zh)
|
2011-10-24 |
2013-06-16 |
Abbvie Inc |
抗骨硬化素(sclerostin)之免疫結合物
|
US20130251703A1
(en)
|
2011-12-05 |
2013-09-26 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3
|
SG11201402739YA
(en)
|
2011-12-05 |
2014-06-27 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
|
EP2788013A4
(de)
|
2011-12-09 |
2015-08-19 |
Stealth Peptides Int Inc |
Aromatisch-kationische peptide und verwendungen davon
|
EP2791175A2
(de)
|
2011-12-14 |
2014-10-22 |
Abbvie Deutschland GmbH & Co. KG |
Zusammensetzung und verfahren zur diagnose und behandlung von durch eisenmangel bedingten erkrankungen
|
EP2791173B1
(de)
|
2011-12-14 |
2020-07-29 |
AbbVie Deutschland GmbH & Co. KG |
Zusammensetzung und verfahren zur diagnose und behandlung von durch eisenmangel bedingten erkrankungen
|
EP3539982A3
(de)
|
2011-12-23 |
2020-01-15 |
Pfizer Inc |
Konstante regionen gentechnisch hergestellter antikörper für stellenspezifische konjugation sowie verfahren und verwendungen dafür
|
TW201333035A
(zh)
|
2011-12-30 |
2013-08-16 |
Abbvie Inc |
針對il-13及/或il-17之雙特異性結合蛋白
|
KR102129234B1
(ko)
|
2012-01-27 |
2020-07-02 |
아비에 도이치란트 게엠베하 운트 콤파니 카게 |
신경돌기 변성과 연관된 질환의 진단 및 치료를 위한 조성물 및 방법
|
JP2015509500A
(ja)
|
2012-02-22 |
2015-03-30 |
ステルス ペプチドズ インターナショナル インコーポレイテッド |
眼疾患を予防または治療するための方法および組成物
|
CA2865409C
(en)
|
2012-02-23 |
2020-07-21 |
Cornell University |
Aromatic-cationic peptides and uses of same
|
KR20170036142A
(ko)
|
2012-03-08 |
2017-03-31 |
할로자임, 아이엔씨 |
조건부 활성 항-표피 성장 인자 수용체 항체 및 이의 사용 방법
|
WO2013184514A1
(en)
|
2012-06-04 |
2013-12-12 |
Irm Llc |
Site-specific labeling methods and molecules produced thereby
|
US9617334B2
(en)
|
2012-06-06 |
2017-04-11 |
Zoetis Services Llc |
Caninized anti-NGF antibodies and methods thereof
|
WO2014011955A2
(en)
|
2012-07-12 |
2014-01-16 |
Abbvie, Inc. |
Il-1 binding proteins
|
AU2013296494B2
(en)
|
2012-08-02 |
2018-04-26 |
Stealth Biotherapeutics Inc. |
Methods for treatment of atherosclerosis
|
AU2013334788A1
(en)
|
2012-10-22 |
2015-06-04 |
Henry Ford Health Systems |
Methods for reducing risks associated with heart failure and factors associated therewith
|
KR20190107184A
(ko)
|
2012-11-01 |
2019-09-18 |
애브비 인코포레이티드 |
항-vegf/dll4 이원 가변 도메인 면역글로불린 및 이의 용도
|
MX2015005874A
(es)
|
2012-11-09 |
2015-09-10 |
Pfizer |
Anticuerpos especificos del factor de crecimiento b derivados de plaquetas y composiciones y usos de estos.
|
JP2016506391A
(ja)
|
2012-12-06 |
2016-03-03 |
ステルス ペプチドズ インターナショナル インコーポレイテッド |
ペプチド治療薬およびその使用方法
|
BR112015014063A2
(pt)
|
2012-12-19 |
2018-10-30 |
Amplimmune Inc |
anticorpos anti-b7-h4 humano e seus usos.
|
EP2935332B1
(de)
|
2012-12-21 |
2021-11-10 |
MedImmune, LLC |
Anti-h7cr antikörpern
|
WO2014124258A2
(en)
|
2013-02-08 |
2014-08-14 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
CN115925957A
(zh)
|
2013-02-08 |
2023-04-07 |
Irm责任有限公司 |
用于修饰抗体以制备免疫缀合物的特定位点
|
CN117752766A
(zh)
|
2013-03-01 |
2024-03-26 |
康德生物医疗有限公司 |
治疗线粒体疾病的方法
|
CN115990241A
(zh)
|
2013-03-01 |
2023-04-21 |
康德生物医疗有限公司 |
预防或治疗巴斯综合征的方法和组合物
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
EP3611189A1
(de)
|
2013-03-14 |
2020-02-19 |
Novartis AG |
Antikörper gegen notch 3
|
EP3564384A1
(de)
|
2013-03-14 |
2019-11-06 |
Abbott Laboratories |
Monoklonale antikörper gegen hcv-core lipid-bindender domäne
|
US9790478B2
(en)
|
2013-03-14 |
2017-10-17 |
Abbott Laboratories |
HCV NS3 recombinant antigens and mutants thereof for improved antibody detection
|
CN105228649B
(zh)
|
2013-03-14 |
2019-01-18 |
雅培制药有限公司 |
Hcv抗原-抗体组合测定和方法以及用在其中的组合物
|
CA2903772A1
(en)
|
2013-03-15 |
2014-09-25 |
Novartis Ag |
Antibody drug conjugates
|
BR112015023797A2
(pt)
|
2013-03-15 |
2017-10-24 |
Abbvie Inc |
proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
EP3586864A1
(de)
|
2013-05-14 |
2020-01-01 |
Stealth Biotherapeutics Corp |
Verfahren zur vorbeugung oder behandlung von linksventrikulärer remodellierung
|
CN106414489A
(zh)
|
2013-05-24 |
2017-02-15 |
米迪缪尼有限公司 |
抗-b7-h5抗体及其用途
|
CA2914369C
(en)
|
2013-06-06 |
2023-02-14 |
Igenica Biotherapeutics, Inc. |
Anti-c10orf54 antibodies and uses thereof
|
ES2753419T3
(es)
|
2013-06-07 |
2020-04-08 |
Univ Duke |
Inhibidores del factor H del complemento
|
US9877997B2
(en)
|
2013-06-26 |
2018-01-30 |
Stealth Biotherapeutics Corp |
Methods and compositions for regulating SRCA2A expression levels in myocardial infarction
|
US10047395B2
(en)
|
2013-06-26 |
2018-08-14 |
Stealth Biotherapeutics Corp |
Methods and compositions for detecting and diagnosing diseases and conditions
|
CA2916497C
(en)
|
2013-06-26 |
2022-07-12 |
Stealth Biotherapeutics Corp |
Methods for the regulation of matrix metalloproteinase expression
|
WO2014210056A1
(en)
|
2013-06-27 |
2014-12-31 |
Stealth Peptides International, Inc. |
Peptide therapeutics and methods for using same
|
WO2015017861A1
(en)
|
2013-08-02 |
2015-02-05 |
Stealth Peptides International, Inc. |
Methods and compositions for the prevention and treatment of friedreich's ataxia
|
US11384149B2
(en)
|
2013-08-09 |
2022-07-12 |
Macrogenics, Inc. |
Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
|
UA116479C2
(uk)
|
2013-08-09 |
2018-03-26 |
Макродженікс, Інк. |
БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
|
EP2839842A1
(de)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bispezifische monovalente Diabodies mit Fähigkeit zur Bindung von CD123 und CD3 und Verwendungen davon
|
EP2840091A1
(de)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bispezifische Diabodies, die gpA33 und CD3 binden können und Anwendungen dieser
|
AU2014318545A1
(en)
|
2013-09-12 |
2016-03-24 |
Halozyme, Inc. |
Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
|
JP2016533318A
(ja)
|
2013-09-17 |
2016-10-27 |
ユニバーシティ ヘルス ネットワーク (ユーエイチエヌ): テクノロジー ディベロップメント アンド コマーシャリゼーション |
Rgma/ネオジェニンのシス相互作用又は脂質ラフトを標的とする剤及び治療方法における該剤の使用
|
WO2015058868A1
(en)
|
2013-10-25 |
2015-04-30 |
Pangaea Biotech, S.L. |
Compositions and methods for the treatment of cancer
|
US10287572B2
(en)
|
2013-11-01 |
2019-05-14 |
Regents Of The University Of Minnesota |
Protein scaffolds and methods of use
|
TWI736515B
(zh)
|
2013-11-13 |
2021-08-21 |
美商輝瑞大藥廠 |
類腫瘤壞死因子之配體1a之專一性抗體及其組合物及用途
|
US9943563B2
(en)
|
2013-12-02 |
2018-04-17 |
Stealth Biotherapeutics Corp |
Compositions and methods for treating vitiligo
|
US20150203592A1
(en)
|
2013-12-02 |
2015-07-23 |
Abbvie Inc. |
Compositions and methods for treating osteoarthritis
|
WO2015109212A1
(en)
|
2014-01-17 |
2015-07-23 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
DK3097122T3
(da)
|
2014-01-24 |
2020-08-10 |
Ngm Biopharmaceuticals Inc |
Antistoffer, der binder beta-klotho-domæne 2, og fremgangsmåder til anvendelse deraf
|
JP6533534B2
(ja)
|
2014-02-14 |
2019-06-19 |
マクロジェニクス,インコーポレーテッド |
膠芽腫の治療に使用するための組成物及びその使用
|
EP3110974A4
(de)
|
2014-02-24 |
2018-01-24 |
Celgene Corporation |
Verfahren zur verwendung eines aktivators von cereblon für neuronale zellexpansion und behandlung von erkrankungen des zentralnervensystems
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
US20150291689A1
(en)
|
2014-03-09 |
2015-10-15 |
Abbvie, Inc. |
Compositions and Methods for Treating Rheumatoid Arthritis
|
AU2015229463A1
(en)
|
2014-03-12 |
2016-09-15 |
Novartis Ag |
Specific sites for modifying antibodies to make immunoconjugates
|
TW202214691A
(zh)
|
2014-03-21 |
2022-04-16 |
美商艾伯維有限公司 |
抗-egfr抗體及抗體藥物結合物
|
JP6832709B2
(ja)
|
2014-05-16 |
2021-02-24 |
メディミューン,エルエルシー |
新生児Fc受容体結合が改変されて治療および診断特性が強化された分子
|
EP3501532A3
(de)
|
2014-05-28 |
2019-07-17 |
Stealth BioTherapeutics Corp |
Therapeutische zusammensetzungen mit frataxin, lactoferrin, sowie mitochondrialen energieerzeugungsenzymen und verwendungen davon
|
EP3502132A1
(de)
|
2014-05-28 |
2019-06-26 |
Stealth BioTherapeutics Corp |
Therapeutische zusammensetzungen mit kleinen therapeutischen molekülen und verwendungen davon
|
SG10201913680PA
(en)
|
2014-05-29 |
2020-03-30 |
Macrogenics Inc |
Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
|
CA2951162C
(en)
|
2014-06-04 |
2019-04-23 |
Tersus Pharmaceuticals, LLC |
Methods of treating chronic dry eye disease using c16:1n7-palmitoleate and derivatives thereof
|
WO2015195737A1
(en)
|
2014-06-17 |
2015-12-23 |
Stealth Peptides International, Inc. |
Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
WO2016011167A1
(en)
|
2014-07-16 |
2016-01-21 |
Dana-Farber Cancer Institute, Inc., Et Al |
Her3 inhibition in low-grade serous ovarian cancers
|
WO2016020791A1
(en)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Ckit antibody drug conjugates
|
US10238748B2
(en)
|
2014-08-12 |
2019-03-26 |
Novartis Ag |
Anti-CDH6 antibody drug conjugates
|
EP3182989B1
(de)
|
2014-08-21 |
2021-04-14 |
Stealth Biotherapeutics Corp |
Peptid d-arg-2',6'-dmt-lys-phe-nh2 zur behandlung von alport-syndrom
|
PE20170894A1
(es)
|
2014-09-26 |
2017-07-12 |
Macrogenics Inc |
Diacuerpos monovalentes biepecificos que son capaces de unir cd19 y cd3 y usos de los mismos
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
CA2967188A1
(en)
|
2014-11-14 |
2016-05-19 |
Novartis Ag |
Antibody drug conjugates
|
EP3227319B1
(de)
|
2014-12-04 |
2019-11-27 |
Novartis AG |
Verfahren und zusammensetzungen mit polypeptiden der klotho-variante
|
KR102493174B1
(ko)
|
2014-12-05 |
2023-01-27 |
신로직 오퍼레이팅 컴퍼니, 인코포레이티드 |
고암모니아혈증과 관련된 질병을 치료하기 위해 공학처리된 박테리아
|
ES2894034T3
(es)
|
2014-12-05 |
2022-02-11 |
Synlogic Operating Co Inc |
Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia
|
WO2016183532A1
(en)
|
2015-05-13 |
2016-11-17 |
Synlogic, Inc. |
Bacteria engineered to treat a disease or disorder
|
US9688967B2
(en)
|
2014-12-05 |
2017-06-27 |
Synlogic, Inc. |
Bacteria engineered to treat diseases associated with hyperammonemia
|
KR20170087500A
(ko)
|
2014-12-11 |
2017-07-28 |
피에르 파브르 메디카먼트 |
항-c10orf54 항체들 및 그들의 용도들
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
US20160206666A1
(en)
|
2014-12-22 |
2016-07-21 |
Synlogic, Inc. |
Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
|
TW201639596A
(zh)
|
2015-01-24 |
2016-11-16 |
艾伯維有限公司 |
用於治療牛皮癬性關節炎之組合物及方法
|
AU2015380455A1
(en)
|
2015-01-26 |
2017-08-03 |
Macrogenics, Inc. |
Multivalent molecules comprising DR5-binding domains
|
WO2016120828A1
(en)
|
2015-01-30 |
2016-08-04 |
Novartis Ag |
Treatment of breast cancer by m-csf antagonist
|
SG11201707025WA
(en)
|
2015-03-02 |
2017-09-28 |
Synlogic Inc |
Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
|
AU2016227493B2
(en)
|
2015-03-03 |
2022-01-20 |
Kymab Limited |
Antibodies, uses & methods
|
EP3882259A1
(de)
|
2015-05-13 |
2021-09-22 |
Synlogic Operating Company, Inc. |
Zur reduzierung von hyperphenylalaninämie manipulierte bakterien
|
RU2715597C2
(ru)
|
2015-05-29 |
2020-03-02 |
Эббви Инк. |
Антитела к cd40 и способы их применения
|
KR102650751B1
(ko)
|
2015-06-03 |
2024-03-22 |
인타르시아 세라퓨틱스 인코포레이티드 |
임플란트 배치 및 제거 시스템들
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
AU2016274311A1
(en)
|
2015-06-10 |
2018-01-18 |
Synlogic Operating Company, Inc. |
Bacteria engineered to treat diseases associated with hyperammonemia
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
US20190194315A1
(en)
|
2015-06-17 |
2019-06-27 |
Novartis Ag |
Antibody drug conjugates
|
WO2016210373A2
(en)
|
2015-06-24 |
2016-12-29 |
Synlogic, Inc. |
Recombinant bacteria engineered for biosafety, pharmaceutical compositions, and methods of use thereof
|
US11066481B2
(en)
|
2015-07-23 |
2021-07-20 |
The Regents Of The University Of California |
Antibodies to coagulation factor XIa and uses thereof
|
KR20180093127A
(ko)
|
2015-07-30 |
2018-08-20 |
마크로제닉스, 인크. |
Pd-1-결합 분자 및 그것의 사용 방법
|
EP3328988A1
(de)
|
2015-07-31 |
2018-06-06 |
Synlogic, Inc. |
Manipulierte bakterien zur behandlung von erkrankungen mit propionatkatabolismus
|
US10729548B2
(en)
|
2016-05-02 |
2020-08-04 |
Howmedica Osteonics Corp. |
Bioactive soft tissue implant and methods of manufacture and use thereof
|
CA2938576A1
(en)
*
|
2015-08-12 |
2017-02-12 |
Howmedica Osteonics Corp. |
Methods for forming scaffolds
|
US11331191B2
(en)
|
2015-08-12 |
2022-05-17 |
Howmedica Osteonics Corp. |
Bioactive soft tissue implant and methods of manufacture and use thereof
|
US11273184B2
(en)
|
2015-08-31 |
2022-03-15 |
Synlogic Operating Company, Inc. |
Bacteria engineered to treat disorders in which oxalate is detrimental
|
CN116059340A
(zh)
|
2015-09-11 |
2023-05-05 |
艾伯维公司 |
用于治疗复发形式的多发性硬化的方法
|
US9862760B2
(en)
|
2015-09-16 |
2018-01-09 |
Novartis Ag |
Polyomavirus neutralizing antibodies
|
WO2017058859A1
(en)
|
2015-09-29 |
2017-04-06 |
Celgene Corporation |
Pd-1 binding proteins and methods of use thereof
|
WO2017059338A1
(en)
|
2015-10-02 |
2017-04-06 |
Cornell University |
Enzyme-responsive peptide nanofiber compositions and uses thereof
|
WO2017070561A1
(en)
|
2015-10-23 |
2017-04-27 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
US11685925B2
(en)
|
2015-10-30 |
2023-06-27 |
Synlogic Operating Company, Inc. |
Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
|
WO2017075485A1
(en)
|
2015-10-30 |
2017-05-04 |
Synlogic, Inc. |
Bacteria engineered to treat disorders in which trimethylamine (tma) is detrimental
|
EP3368696A1
(de)
|
2015-10-30 |
2018-09-05 |
Synlogic Operating Company, Inc. |
Manipulierte bakterien zur behandlung von krankheiten, die von reduzierter darmentzündung und/oder verstärkter darmschleimhautbarriere profitieren
|
ES2925049T3
(es)
|
2015-11-16 |
2022-10-13 |
Synlogic Operating Co Inc |
Bacterias manipuladas para reducir la hiperfenilalaninemia
|
US10875920B2
(en)
|
2015-12-02 |
2020-12-29 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
|
EP3383908A1
(de)
|
2015-12-02 |
2018-10-10 |
Stsciences, Inc. |
Spezifische antikörper gegen glykosylierten btla (b- und t-lymphozyt-attenuator)
|
US10954301B2
(en)
|
2015-12-14 |
2021-03-23 |
Macrogenics, Inc. |
Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
|
EP3399993B1
(de)
|
2016-01-06 |
2021-03-31 |
D. Travis Wilson |
Verfahren zur behandlung von duchenne-muskeldystrophie
|
WO2017123592A1
(en)
|
2016-01-11 |
2017-07-20 |
Synlogic, Inc. |
Bacteria engineered to treat disorders associated with bile salts
|
WO2017123610A2
(en)
|
2016-01-11 |
2017-07-20 |
Synlogic, Inc. |
Bacteria engineered to detoxify deleterious molecules
|
WO2017125897A1
(en)
|
2016-01-21 |
2017-07-27 |
Novartis Ag |
Multispecific molecules targeting cll-1
|
JP2019503786A
(ja)
*
|
2016-01-25 |
2019-02-14 |
スミス アンド ネフュー インコーポレイテッド |
整形外科用インプラント
|
SG10201913699QA
(en)
|
2016-05-16 |
2020-03-30 |
Intarcia Therapeutics Inc |
Glucagon-receptor selective polypeptides and methods of use thereof
|
AU2017267969A1
(en)
|
2016-05-19 |
2018-12-13 |
Stealth Biotherapeutics Inc. |
Compositions and methods for the prevention and treatment of mitochondrial myopathies
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
LT3458479T
(lt)
|
2016-06-08 |
2021-02-25 |
Abbvie Inc. |
Anti-b7-h3 antikūnai ir antikūnų vaisto konjugatai
|
CA3027033A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
BR112018075653A2
(pt)
|
2016-06-08 |
2019-08-27 |
Abbvie Inc |
anticorpos anti-b7-h3 e conjugados anticorpo fármaco
|
CA3029622A1
(en)
|
2016-07-01 |
2018-01-04 |
Dana-Farber Cancer Institute, Inc. |
Compositions, assays, and methods for direct modulation of fatty acid metabolism
|
SG11201901950TA
(en)
|
2016-09-19 |
2019-04-29 |
Celgene Corp |
Methods of treating immune disorders using pd-1 binding proteins
|
JP2019534859A
(ja)
|
2016-09-19 |
2019-12-05 |
セルジーン コーポレイション |
Pd−1結合タンパク質を使用して白斑を治療する方法
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
JP7274417B2
(ja)
|
2016-11-23 |
2023-05-16 |
イミュノア・セラピューティクス・インコーポレイテッド |
4-1bb結合タンパク質及びその使用
|
AU2018206539A1
(en)
|
2017-01-03 |
2019-07-18 |
Intarcia Therapeutics, Inc. |
Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
KR20200024158A
(ko)
|
2017-05-31 |
2020-03-06 |
주식회사 에스티큐브앤컴퍼니 |
Btn1a1에 면역특이적으로 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
|
EP3630835A1
(de)
|
2017-05-31 |
2020-04-08 |
STCube & Co., Inc. |
Antikörper und moleküle, die immunspezifisch an btn1a1 binden, und therapeutische verwendungen davon
|
KR20200026209A
(ko)
|
2017-06-06 |
2020-03-10 |
주식회사 에스티큐브앤컴퍼니 |
Btn1a1 또는 btn1a1-리간드에 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
|
WO2018237198A1
(en)
|
2017-06-21 |
2018-12-27 |
Synlogic Operating Company, Inc. |
BACTERIA FOR THE TREATMENT OF DISORDERS
|
JP2020530457A
(ja)
|
2017-08-08 |
2020-10-22 |
メモリアル スローン ケタリング キャンサー センター |
Mek阻害剤治療によって惹起される皮膚反応を治療するbraf阻害剤の使用
|
US20220031776A1
(en)
|
2017-09-08 |
2022-02-03 |
Keio University |
Bacteriophage for modulating inflammatory bowel disease
|
SG11202003930YA
(en)
|
2017-12-01 |
2020-05-28 |
Pfizer |
Anti-cxcr5 antibodies and compositions and uses thereof
|
JP2021508439A
(ja)
|
2017-12-01 |
2021-03-11 |
ノバルティス アーゲー |
ポリオーマウイルス中和抗体
|
MX2020009526A
(es)
|
2018-03-12 |
2020-10-28 |
Zoetis Services Llc |
Anticuerpos anti-ngf y metodos de estos.
|
WO2019190984A1
(en)
|
2018-03-29 |
2019-10-03 |
Pfizer Inc. |
Lfa3 variants and compositions and uses thereof
|
US10640576B2
(en)
|
2018-04-10 |
2020-05-05 |
Y-Biologics Inc. |
Cell engaging binding molecules
|
CN112165974A
(zh)
|
2018-05-31 |
2021-01-01 |
诺华股份有限公司 |
乙型肝炎抗体
|
EP3802611A2
(de)
|
2018-06-01 |
2021-04-14 |
Novartis AG |
Bindungsmoleküle gegen bcma und deren verwendungen
|
JP2021531007A
(ja)
|
2018-07-20 |
2021-11-18 |
ピエール、ファーブル、メディカマン |
Vistaに対する受容体
|
SG11202100888WA
(en)
|
2018-09-07 |
2021-02-25 |
Pfizer |
Anti-avb8 antibodies and compositions and uses thereof
|
WO2020053742A2
(en)
|
2018-09-10 |
2020-03-19 |
Novartis Ag |
Anti-hla-hbv peptide antibodies
|
US11931397B2
(en)
|
2018-12-06 |
2024-03-19 |
Stealth Biotherapeutics Inc. |
Methods and compositions for the treatment of Sengers syndrome
|
TW202039554A
(zh)
|
2018-12-19 |
2020-11-01 |
瑞士商諾華公司 |
抗TNF-α抗體
|
CA3234463A1
(en)
|
2018-12-21 |
2019-12-18 |
Novartis Ag |
Antibodies to pmel17 and conjugates thereof
|
AU2020231609A1
(en)
|
2019-03-07 |
2021-10-28 |
Biomx Ltd. |
Bacteriophage for modulating inflammatory bowel disease
|
KR102563319B1
(ko)
|
2019-03-08 |
2023-08-03 |
앱티스 주식회사 |
위치특이적 항체 콘쥬게이션 및 이의 구체예로서의 항체-약물 콘쥬게이트
|
TW202102526A
(zh)
|
2019-04-04 |
2021-01-16 |
美商銳進科斯生物股份有限公司 |
重組腺相關病毒及其用途
|
WO2020223345A1
(en)
|
2019-04-29 |
2020-11-05 |
Antipov Eugene |
Enumeration of genetically engineered microorganisms by live cell counting techniques
|
US11518877B2
(en)
*
|
2019-05-07 |
2022-12-06 |
Ut-Battelle, Llc |
Toughened polyester composites containing polyester matrix and droplets of high boiling liquid therein
|
WO2020237491A1
(en)
|
2019-05-28 |
2020-12-03 |
Shanghaitech University |
Composition and methods to treat ectodermal dysplasia 2, clouston type
|
JP2022542882A
(ja)
|
2019-07-24 |
2022-10-07 |
ステルス バイオセラピューティクス インコーポレイテッド |
神経変性疾患の治療におけるペプチド模倣化合物(r)-2-アミノ-n-((s)-l-(((s)-5-アミノ-l-(3-ベンジル-1,2,4-オキサジアゾール-5-イル)ペンチル)アミノ)-3-(4-ヒドロキシ-2,6-ジメチルフェニル)-i-オキソプロパン-2-イル)-5-グアニジノペンタンアミド
|
JP2022544004A
(ja)
|
2019-07-26 |
2022-10-17 |
リジェネックスバイオ インコーポレイテッド |
操作された核酸調節エレメントならびにその使用方法
|
CN114364389A
(zh)
|
2019-09-24 |
2022-04-15 |
普罗莱克塔生物科学公司 |
用于治疗炎性和免疫疾病的组合物和方法
|
WO2021062323A1
(en)
|
2019-09-26 |
2021-04-01 |
Stcube & Co. |
Antibodies specific to glycosylated ctla-4 and methods of use thereof
|
CA3156499A1
(en)
|
2019-10-04 |
2021-04-08 |
Stealth Biotherapeutics Inc. |
CHINONE, HYDROCHINONE AND NAPHTOCHINONE ANALOGS OF VATIQUINONE FOR THE TREATMENT OF DISEASES WITH MITOCHONDRIAL DISORDERS
|
WO2021072277A1
(en)
|
2019-10-09 |
2021-04-15 |
Stcube & Co. |
Antibodies specific to glycosylated lag3 and methods of use thereof
|
AU2021240078A1
(en)
|
2020-03-20 |
2022-09-01 |
Synlogic Operating Company, Inc. |
Microorganisms engineered to reduce hyperphenylalaninemia
|
WO2021202473A2
(en)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Engineered antibodies
|
WO2021202463A1
(en)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Anti-rsv antibodies
|
CN115996916A
(zh)
|
2020-04-03 |
2023-04-21 |
康德生物医疗有限公司 |
用于预防和/或治疗包括弗里德赖希共济失调的线粒体疾病的组合物和方法
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
CN116096758A
(zh)
|
2020-05-01 |
2023-05-09 |
诺华股份有限公司 |
工程化免疫球蛋白
|
CN115461363A
(zh)
|
2020-05-01 |
2022-12-09 |
诺华股份有限公司 |
免疫球蛋白变体
|
MX2023003699A
(es)
|
2020-10-07 |
2023-04-21 |
Regenxbio Inc |
Virus adenoasociados para el suministro ocular de genoterapia.
|
WO2022076750A2
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns or muscle delivery
|
WO2022097060A1
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
MX2023005234A
(es)
|
2020-11-06 |
2023-05-18 |
Novartis Ag |
Terapia de combinacion de agente anti-cd19 y agente de direccionamiento a celulas b para el tratamiento de neoplasias malignas de celulas b.
|
CN116472288A
(zh)
|
2020-11-06 |
2023-07-21 |
诺华股份有限公司 |
抗体Fc变体
|
EP4256039A2
(de)
|
2020-12-02 |
2023-10-11 |
Synlogic Operating Company, Inc. |
Manipulierte mikroorganismen
|
WO2022146718A1
(en)
|
2020-12-31 |
2022-07-07 |
Synlogic Operating Company, Inc. |
Microorganisms engineered to reduce hyperphenylalaninemia
|
EP4271482A2
(de)
|
2020-12-31 |
2023-11-08 |
Alamar Biosciences, Inc. |
Bindemoleküle mit hoher affinität und/oder spezifität sowie verfahren zur herstellung und verwendung davon
|
EP4277634A1
(de)
|
2021-01-12 |
2023-11-22 |
Prolacta Bioscience, Inc. |
Synbiotische behandlungsschemata
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
WO2022221273A1
(en)
|
2021-04-13 |
2022-10-20 |
Synlogic Operating Company, Inc. |
Bacteria engineered to secrete active proteins
|
CA3216880A1
(en)
|
2021-04-16 |
2022-10-20 |
Novartis Ag |
Antibody drug conjugates and methods for making thereof
|
CA3226019A1
(en)
|
2021-07-20 |
2023-01-26 |
Ags Therapeutics Sas |
Extracellular vesicles from microalgae, their preparation, and uses
|
WO2023044479A1
(en)
|
2021-09-17 |
2023-03-23 |
Synlogic Operating Company, Inc. |
Methods for reducing hyperphenylalaninemia
|
WO2023060269A1
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for targeted delivery
|
WO2023060272A2
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
WO2023069255A1
(en)
|
2021-10-20 |
2023-04-27 |
Stealth Biotherapeutics Inc. |
Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions
|
WO2023073599A1
(en)
|
2021-10-28 |
2023-05-04 |
Novartis Ag |
Engineered fc variants
|
WO2023077092A1
(en)
|
2021-10-28 |
2023-05-04 |
Regenxbio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
WO2023101963A2
(en)
|
2021-11-30 |
2023-06-08 |
Northwestern University |
Compositions for inhibiting dipeptide repeat protein-ribosomal rna interaction and uses thereof
|
WO2023131901A1
(en)
|
2022-01-07 |
2023-07-13 |
Johnson & Johnson Enterprise Innovation Inc. |
Materials and methods of il-1beta binding proteins
|
WO2023133321A1
(en)
|
2022-01-10 |
2023-07-13 |
Stealth Biotherapeutics Inc. |
Small molecule peptidomimetic for the treatment of tauopathies
|
WO2023144127A1
(en)
|
2022-01-31 |
2023-08-03 |
Ags Therapeutics Sas |
Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
|
WO2023152633A1
(en)
|
2022-02-09 |
2023-08-17 |
Janssen Biotech, Inc. |
Methods and compositions comprising v beta 17 bispecific t cell engagers and bioengineered virus specific lymphocytes
|
WO2023178053A1
(en)
|
2022-03-13 |
2023-09-21 |
Regenxbio Inc. |
Modified muscle-specific promoters
|
WO2023201308A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Gene therapy for treating an ocular disease
|
WO2023201277A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
WO2023205610A2
(en)
|
2022-04-18 |
2023-10-26 |
Regenxbio Inc. |
Hybrid aav capsids
|
US20230357381A1
(en)
|
2022-04-26 |
2023-11-09 |
Novartis Ag |
Multispecific antibodies targeting il-13 and il-18
|
WO2023232976A1
(en)
|
2022-06-03 |
2023-12-07 |
Ags Therapeutics Sas |
Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses
|
WO2023245171A1
(en)
|
2022-06-17 |
2023-12-21 |
Synlogic Operating Company, Inc. |
Bacteria engineered to treat diseases associated with bile acid metabolism and methods of use thereof
|
WO2023245168A1
(en)
|
2022-06-17 |
2023-12-21 |
Synlogic Operating Company, Inc. |
Bacteria engineered to treat diseases associated with bile acid metabolism and methods of use thereof
|
WO2023250478A1
(en)
|
2022-06-23 |
2023-12-28 |
Synlogic Operating Company, Inc. |
Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|
WO2024018426A1
(en)
|
2022-07-22 |
2024-01-25 |
Janssen Biotech, Inc. |
Enhanced transfer of genetic instructions to effector immune cells
|
WO2024028732A1
(en)
|
2022-08-05 |
2024-02-08 |
Janssen Biotech, Inc. |
Cd98 binding constructs for treating brain tumors
|
WO2024028731A1
(en)
|
2022-08-05 |
2024-02-08 |
Janssen Biotech, Inc. |
Transferrin receptor binding proteins for treating brain tumors
|
WO2024044725A2
(en)
|
2022-08-24 |
2024-02-29 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
WO2024081746A2
(en)
|
2022-10-11 |
2024-04-18 |
Regenxbio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
WO2024081768A1
(en)
|
2022-10-12 |
2024-04-18 |
Synlogic Operating Company, Inc. |
Bacteria engineered to produce active epidermal growth factor (egf) and their medical uses
|